|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,560.00 GBX | +1.66% |
|
-3.32% | -1.67% |
| 12:30pm | HSBC chair to join PM Starmer on China visit next week - Sky | AN |
| 11:22am | Daiichi and AstraZeneca's Enhertu wins sixth approval in China | AN |
| Capitalization | 278B 237B 220B 206B 384B 25,454B 407B 2,508B 994B 12,024B 1,042B 1,021B 43,999B | P/E ratio 2025 * |
27.5x | P/E ratio 2026 * | 23.9x |
|---|---|---|---|---|---|
| Enterprise value | 300B 255B 237B 222B 413B 27,438B 438B 2,703B 1,071B 12,961B 1,123B 1,100B 47,428B | EV / Sales 2025 * |
5.12x | EV / Sales 2026 * | 4.73x |
| Free-Float |
96.62% | Yield 2025 * |
1.81% | Yield 2026 * | 1.91% |
Last Transcript: AstraZeneca PLC
| 1 day | +1.98% | ||
| 1 week | -3.32% | ||
| Current month | -1.67% | ||
| 1 month | -0.53% | ||
| 3 months | +8.13% | ||
| 6 months | +30.99% | ||
| Current year | -1.67% |
| 1 week | 13,268 |  | 14,188 |
| 1 month | 13,268 | | 14,410 |
| Current year | 13,268 | | 14,410 |
| 1 year | 9,573.5 | | 15,474.36 |
| 3 years | 9,461 | | 15,474.36 |
| 5 years | 6,736 | | 15,474.36 |
| 10 years | 3,680 | | 15,474.36 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 65 | 30/09/2012 |
Aradhana Sarin
DFI | Director of Finance/CFO | 52 | 31/07/2021 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 31/07/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 05/04/1999 | |
Pascal Soriot
BRD | Director/Board Member | 65 | 30/09/2012 |
Philip Broadley
BRD | Director/Board Member | 65 | 26/04/2017 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -0.79% | 8.29% | 64 M€ | |
| +5.00% | 5.39% | 1,470 M€ | |
| +0.32% | 5.17% | 26 M€ | |
| +3.27% | 4.89% | 847 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.66% | -3.32% | +22.83% | +22.85% | 278B | |
| +1.13% | +5.48% | +44.51% | +218.39% | 966B | |
| +0.58% | -0.10% | +51.00% | +30.33% | 525B | |
| +0.83% | +0.56% | +28.82% | +46.73% | 382B | |
| +0.93% | +0.64% | +27.06% | +17.75% | 371B | |
| +0.66% | +0.54% | +28.27% | +34.73% | 276B | |
| -1.56% | -1.35% | +14.42% | -0.37% | 276B | |
| +6.11% | +8.63% | -31.79% | -17.82% | 260B | |
| +1.36% | +5.56% | +27.41% | +33.49% | 185B | |
| +1.93% | +8.68% | +41.65% | +58.34% | 160B | |
| Average | +1.42% | -0.33% | +25.42% | +44.44% | 367.94B | |
| Weighted average by Cap. | +1.23% | -0.48% | +30.55% | +75.56% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 58.49B 49.78B 46.24B 43.35B 80.72B 5,358B 85.58B 528B 209B 2,531B 219B 215B 9,261B | 62.02B 52.79B 49.02B 45.96B 85.59B 5,681B 90.74B 560B 222B 2,683B 233B 228B 9,819B |
| Net income | 10.32B 8.78B 8.15B 7.64B 14.24B 945B 15.09B 93.09B 36.89B 446B 38.68B 37.89B 1,633B | 11.93B 10.15B 9.43B 8.84B 16.46B 1,092B 17.45B 108B 42.65B 516B 44.73B 43.81B 1,888B |
| Net Debt | 21.66B 18.43B 17.12B 16.05B 29.89B 1,984B 31.69B 195B 77.45B 937B 81.22B 79.55B 3,429B | 15.76B 13.41B 12.46B 11.68B 21.75B 1,444B 23.06B 142B 56.36B 682B 59.1B 57.89B 2,495B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/01/26 | 13,560.00 p | +1.66% | 2,229,114 |
| 21/01/26 | 13,338.00 p | -1.35% | 2,380,280 |
| 20/01/26 | 13,520.00 p | -2.66% | 3,045,769 |
| 19/01/26 | 13,890.00 p | -1.15% | 1,537,042 |
| 16/01/26 | 14,052.00 p | +0.19% | 3,712,617 |
Delayed Quote London S.E., January 22, 2026 at 04:35 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AZN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition